Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta

Minji Park1, Yong-Joon Cho2, Yang Won Lee3,4

  • 1Department of Systems Biotechnology, Chung-Ang University, Anseong, South Korea.

Insights

Ketoconazole resistance in Malassezia restricta is linked to gene copy number increases and drug efflux pump upregulation. These genetic changes explain how this common skin fungus evades antifungal treatment.

Area of Science:

  • Medical Mycology
  • Genomics
  • Antimicrobial Resistance

Background:

  • Malassezia restricta is an opportunistic human skin fungus implicated in conditions like dandruff and seborrheic dermatitis.
  • Ketoconazole is a common antifungal treatment for M. restricta-associated skin diseases.
  • Emergence of ketoconazole-resistant M. restricta strains poses a challenge to effective treatment.

Purpose of the Study:

  • To elucidate the genomic mechanisms underlying ketoconazole resistance in clinical isolates of Malassezia restricta.
  • To compare the genomes of resistant strains with a susceptible reference strain to identify genetic differences.

Main Methods:

  • Clinical isolation of ketoconazole-resistant M. restricta strains.
  • Whole-genome sequencing and comparative genomic analysis.
  • Gene expression analysis and functional validation in Cryptococcus neoformans.

Main Results:

  • Identified tandem multiplications of genomic loci containing ATM1 and ERG11 homologs in resistant strains.
  • Observed increased expression of ATM1 and ERG11, correlating with copy number variations.
  • Confirmed upregulation of the PDR5 homolog (drug efflux pump) and increased drug efflux in resistant strains.

Conclusions:

  • Ketoconazole resistance in M. restricta is multifactorial, involving gene duplication (ATM1, ERG11) and drug efflux pump (PDR5) overexpression.
  • These genetic alterations impact ergosterol synthesis, mitochondrial function, and drug tolerance.
  • Understanding these mechanisms is crucial for developing strategies to overcome antifungal resistance in M. restricta.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
261
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
981